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Abstract
T46I is the second mutation on the hVAPB MSP domain which was recently identified from non-Brazilian kindred to cause a
familial amyotrophic lateral sclerosis (ALS). Here using CD, NMR and molecular dynamics (MD) simulations, we characterized
the structure, stability, dynamics and binding capacity of the T46I-MSP domain. The results reveal: 1) unlike P56S which we
previously showed to completely eliminate the native MSP structure, T46I leads to no significant disruption of the native
secondary and tertiary structures, as evidenced from its far-UV CD spectrum, as well as Ca and Cb NMR chemical shifts. 2)
Nevertheless, T46I does result in a reduced thermodynamic stability and loss of the cooperative urea-unfolding transition.
As such, the T46I-MSP domain is more prone to aggregation than WT at high protein concentrations and temperatures in
vitro, which may become more severe in the crowded cellular environments. 3) T46I only causes a 3-fold affinity reduction to
the Nir2 peptide, but a significant elimination of its binding to EphA4. 4) EphA4 and Nir2 peptide appear to have overlapped
binding interfaces on the MSP domain, which strongly implies that two signaling networks may have a functional interplay
in vivo. 5) As explored by both H/D exchange and MD simulations, the MSP domain is very dynamic, with most loop residues
and many residues on secondary structures highly fluctuated or/and exposed to bulk solvent. Although T46I does not alter
overall dynamics, it does trigger increased dynamics of several local regions of the MSP domain which are implicated in
binding to EphA4 and Nir2 peptide. Our study provides the structural and dynamic understanding of the T46I-causing ALS;
and strongly highlights the possibility that the interplay of two signaling networks mediated by the FFAT-containing
proteins and Eph receptors may play a key role in ALS pathogenesis.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most prevalent fatal
motor neuron disease, which affects people of all race and ethnic
background. Approximately 10% of the cases have hereditary
background while the rest are sporadic. Seven ALS-causative
genes have been identified to date but the most characterized is
ALS1 encoding mutants of Cu/Zn-superoxide dismutase (SOD1).
So far, despite intense studies, the exact mechanism underlying
ALS pathogenesis remains poorly understood and there is no
efficient therapy for ALS. As sporadic and familial ALS affects the
same neurons with similar pathology, it is believed that knowledge
and therapeutic approaches/agents developed on mutant models
can be translated to sporadic ALS [1,2].
Recently, ALS8 was identified from a large Brazilian family
with dominant motor neuron diseases, which encodes a mutated
VAPB (vesicle-associated membrane protein-associated protein B).
The missense P56S point mutation results in a typical ALS
phenotype with rapid progression or late onset spinal muscular
atrophy [2–5]. Very recently, another mutation T46I on VAPB
has been unraveled to also cause ALS in non-Brazilian kindred
[6]. The human VAP family proteins were originally identified as
homologues of vesicle-associated membrane protein (VAMP)-
associated protein (VAP) in Aplysia californica (aVAP33) [7,8], which
include VAPA, VAPB, and VAPC. VAPA and VAPB share
,60% sequence identity while VAPB and VAPC are alternatively
spliced variants. VAP proteins are ubiquitously expressed, type II
integral membrane proteins that localize to the endoplasmic
reticulum (ER) and pre-Golgi intermediates [9], which have been
implicated in the regulation of neurotransmitter release, ER-Golgi
and intra-Golgi transport [10,11]. Moreover, VAP proteins have
been shown to target lipid-binding proteins carrying a short motif
with two phenylalanines in an acidic tract (FFAT motif) to the ER
[12,13]. The FFAT motif with the consensus amino acid sequence
EFFDAxE was conserved in several lipid-binding protein families
involved in the transfer of lipids between the ER and other
organelles [14–18]. The VAP proteins also interact with
intracellular proteins [19,20] including Nir1, Nir2, and Nir3 via
the FFAT motif which differentially affects the organization of the
ER [11].
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proteins are composed of three conserved domains, namely an N-
terminal immunoglobulin-like b sheet domain with 22% sequence
identity to the major sperm protein (MSP), a central coiled-coil
domain, and a C-terminal transmembrane domain. After the
P56S mutation was identified to be associated to ALS, the VAPB-
MSP domain received intensive studies regarding its functions and
the biological consequence of the mutation [21–28]. The P56S
mutation results in severe aggregation and alteration of unfolded
protein response (UPR) in ER [6,21–28]. Strikingly, the cleaved
VAPB MSP domain was recently found to act as a novel ligand
class for Eph receptors [29]. The connection of VAPB to Eph
receptors may shed critical light on the core signaling networks
involved in ALS pathogenesis and also represent a promising
target for therapeutic interventions [30]. Indeed, Eph receptors
constitute the largest family of tyrosine kinases, with 16 members
in mammals and chick divided into two classes, EphA and EphB,
which are respectively activated by six glycosylphosphatidylinosi-
tol-anchored ephrin-A ligands or three transmembrane ephrin-B
ligands to mediate an extremely wide spectrum of biological
functions through signals that are generated by both receptor and
ligand activation [31].
Previously, we have determined the crystal structure of the
hVAPB MSP domain, which adopts a well-defined MSP fold with
a cooperative urea-unfolding transition [32]. Moreover, with our
discovery that insoluble proteins could in fact be solubilized in salt-
free water [33–35], we have succeeded in characterizing the P56S
mutant by NMR spectroscopy and demonstrated that the P56S
mutation completely eliminates the native MSP structure and
binding capacity. In particular, the unstructured P56S mutant
becomes severely aggregated in buffers mimicking the physiolog-
ical conditions [32].
In the present study, we aimed to characterize the newly-
identified T46I mutant. By extensive CD, NMR characterization
and molecular dynamics (MD) simulations, we found that the
T46I-MSP domain still retains the native MSP structure with
overall dynamics largely unaltered. Nevertheless the T46I
mutation on the MSP domain does lead to a reduction of its
thermodynamic stability and loss of the cooperative urea-
unfolding transition. As such, the T46I-MSP domain is much
more prone to aggregation at high protein concentrations and
temperatures. Noticeably, the T46I mutation results in only a 3-
fold reduction of its binding affinity to the Nir2 peptide, but a
significant abolishment of the binding ability to EphA4.
Methods
Cloning, expression, and purification of the WT and T46I
MSP domains
The DNA fragment encoding the wild-type (WT) hVAPB MSP
domain (residues 1–125) was cloned into a modified pET32a
vector (Novagen) as previously described [32]. The T46I mutation
on the MSP domain was generated by use of site-directed
mutagenesis [36]. The vectors were transformed into E. coli BL21
(DE3) cells (Novagen) for protein expression. Most WT and a
small portion of T46I proteins were found in supernatant and thus
were first purified by Ni
2+-affinity chromatography (Qiagen) under
the native condition, followed by in-gel cleavage to remove the
His-tag. The released WT and T46I proteins were further purified
on an AKTA FPLC machine (Amersham Biosciences) using a gel
filtration column (HiLoad 16/60 Superdex 200), followed by an
anion-exchange column (Mono Q 5/50). The generation and
purification of the EphA4 ligand-binding domain (181 residues)
followed the protocol we previously established [37].
The production of the isotope-labeled MSP and EphA4 proteins
for NMR studies followed a similar procedure except that the
bacteria were grown in M9 medium with the addition of
[
15NH4]2SO4 for
15N labeling and [
15NH4]2SO4/[
13C]-glucose
for
15N-/
13C double labeling [32,37]. The purity of all protein
samples was checked by the SDS-PAGE gel and their molecular
weights were verified by a Voyager STR matrix-assisted laser
desorption ionization time-of-flight-mass spectrometer (Applied
Biosystems). The concentration of protein samples was determined
by the spectroscopic method in the presence of denaturant [38].
Structure and thermodynamic stability as measured by
Circular Dichroism [CD]
All CD experiments were carried out in a Jasco J-810
spectropolarimeter (Jasco Corporation, Tokyo, Japan) as previ-
ously described [32–35]. The protein concentration is 20 mM for
all far-UV CD experiments. To measure the thermodynamic
stability of the T46I-MSP domain, a series of far-UV CD spectra
were collected by varying the urea concentrations from 0 to 8 M
and subsequently the unfolding curve was constructed by plotting
the ellipiticity values at 222 nm versus the molar concentration of
urea [32].
ITC characterization of binding activity
Isothermal titration calorimetry (ITC) experiments were
performed using a Microcal VP machine as previously described
[35]. The Nir2 peptide (EEEFFDAHE) was purchased from
Genesis Biotech Inc. and further purified by HPLC on a reverse-
phase C18 column. Titrations were conducted in the buffer
(50 mM Tris-HCl, 150 mM NaCl, 2 mM DTT, pH 7.5) at 25uC.
The peptide or EphA4 (300 mM) was loaded into the syringe while
the wild-type hVAPB MSP protein (10 mM) was placed in the
sample cell. To obtain thermodynamic binding parameters, the
titration data after subtracting the blank values were fitted to a
single binding site model using the built-in software ORIGIN
version 5.0 (Microcal Software Inc.).
NMR experiments
The T46I-MSP sample was prepared in 10 mM phosphate
buffer, pH 6.8. All NMR data were collected at 25uC on an 800-
MHz Bruker Avance spectrometer equipped with a shielded
cryoprobe as described before [32,35]. For HSQC characteriza-
tion, samples were prepared at a protein concentration of 100 mM
while for achieving sequential assignments, triple-resonance
experiments including HNCACB and CBCA(CO)NH were
acquired on a double-labeled sample at a protein concentration
of ,200 mM. The spectral processing and analysis was performed
by using the program DANGLE in CCPNMR [39].
To conduct hydrogen-deuterium (H/D) exchange experiments,
the
15N-labeled WT- or T46I-MSP domains in the 10 mM (pH
6.8) phosphate buffer was lyophilized and then re-dissolved in
D2O. Progress of the exchange process between amide protons
and deuterium was followed by collecting a series of successive
HSQC spectra starting immediately after the sample re-solubili-
zation in D2O. All exchange experiments were conducted on an
800 MHz Bruker Avance spectrometer at 25uC. The first HSQC
spectrum was collected after 15 min, and the last spectra were
acquired after 2.5 h.
For NMR HSQC characterization of the binding interactions of
WT-/T46I-MSP to the Nir2 peptide; as well as to the EphA4
ligand-binding domain, two-dimensional
1H-
15N HSQC spectra
of the
15N-labeled WT-/T46I-MSP domains were acquired at a
protein concentration of 100 mM in the absence or presence of the
Consequence of the ALS-Causing T46I Mutation
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1:1; 1:2; 1:4; 1:6; and 1:8. Similarly, the binding interactions were
also visualized by collecting HSQC spectra of the
15N-labeled
EphA4 ligand-binding domain at a protein concentration of
100 mM in the absence or presence of WT- or T46I-MSP domain
at the same molar ratios. By superimposing the HSQC spectra, the
shifted or disappeared HSQC peaks could be identified and
further assigned to the corresponding residues of the WT-/T46I-
MSP domains or EphA4 ligand-binding domain whose assignment
was previously achieved [37,40,41].
Molecular docking of the MSP-EphA4 complex
The models of the MSP-EphA4 complex were constructed as
we previously conducted on other systems [37,41], by use of the
HADDOCK software [42] in combination with CNS [43], which
makes use of chemical shift perturbation data to derive the docking
while allowing various degrees of flexibility. The docking
procedure was performed by three steps as follows: first,
randomization and rigid body energy minimization; second,
semi-flexible simulated annealing; and third, flexible explicit
solvent refinement. All MSP and EphA4 residues with HSQC
peaks disappeared and significantly shifted were set to be ‘‘active’’
residues, whereas neighbors of active residues were defined as
‘‘passive’’ residues according to HADDOCK definition. One
thousand structures were generated during the rigid body docking,
and the best 50 structures were selected for semi-flexible simulated
annealing, followed by water refinement. 2 structures with the
lowest energies were selected for detailed analysis and display.
Molecular dynamics (MD) simulations
To unravel the dynamic behaviors of both WT- and T46I-MSP
domains, two independent, 15-ns MD simulations were performed
for each of them. The WT-MSP structure used for MD
simulations was 3IKK we previously determined [35]. As our
current experimental results clearly indicate that the T46I-MSP
domain still has the structure highly similar to the WT-MSP
domain, the initial T46I structure was generated by using
Mutagenesis command in pymol (www.pymol.org) to mutate the
Thr46 residue to Ile with the option of backbone-dependent
rotamers. Out of 5 Ile rotamers, we picked the one that has the
highest representation of 81.9%, which has the least steric
hindrance. This initial T46I structure was subsequently subjected
to a 5000-step energy minimization using steepest descent
algorithm and position restraint equilibration for 200 ps.
Simulations for both the WT- and T46I-MSP domains were set
up as previously described [36]. Briefly, the simulation cell is a
periodic cubic box with a minimum distance of 9 A ˚ between the
protein and the box walls to ensure the proteins would not directly
interact with its own periodic image. The water molecules,
described using the TIP3P model, were filled in the periodic cubic
box for the all atom simulation. Each set of MD simulations was
implemented by using the program GROMACS [44] for 15 ns,
with the AMBER 99SB-ILDN all-atom force field [45]. The long-
range electrostatic interactions were treated using the fast particle-
mesh Ewald summation method [46]. The temperature during
simulations was kept constant at 300 K by Berendsen’s coupling.
The pressure was held at 1 bar. The isothermal compressibility
was 4.6*10
25 bar
21. The time step was set as 2 fs. All bond
lengths including hydrogen atoms were constrained by the LINCS
algorithm [47]. Prior to MD simulations, all the initial structures
were relaxed by 5000 steps of energy minimization using steepest
descent algorithm, followed by position restraint equilibration for
200 ps.
Results
Structure and thermodynamic stability of the T46I-MSP
domain
In the present study, by using site-directed mutagenesis we
constructed the T46I-MSP domain by replacing Thr46 with Ile on
the WT-MSP domain we previously generated [32]. Subsequently
the T46I-MSP domain was expressed in E. coli BL21 cells.
Although a large portion of the T46I protein existed in inclusion
body, there was a small portion of the soluble T46I form in
supernatant. Consequently we purified the soluble T46I protein by
Ni
2+-affinity column under native condition, followed by FPLC
ion-exchange chromatography. The purified T46I domain with
His-tag removed has a far-UV CD spectrum highly similar to that
of WT (Figure 1a). This strongly indicates that T46I has a native-
like secondary structure. Furthermore, the T46I-MSP domain also
has a well-dispersed HSQC spectrum (Figure 1b) in which many
peaks are even superimposable to those of WT, suggesting that
T46I is also well-folded. Despite the aggregation of T46I at protein
concentrations higher .300 mM, we managed to collect a pair of
triple-resonance NMR spectra, namely HNCACB and CBCA
(CO)NH, on a double-labeled sample at a protein concentration of
,200 mM, which thus allowed our successful sequential assign-
ment. Although HSQC peaks of three regions were not detectable
for T46I, including residues Ile46-Tyr52, Glu82-Ser84 and C-
terminal Ph123-Leu125, Ca and Cb chemical shifts of the
remaining T46I residues are almost identical to those of WT
(Figures 1c, 1d and 1e). These results provide the strongest
evidence that the T46I-MSP domain assumes a three-dimensional
structure highly similar to that of WT.
Thermodynamic stability is an important factor mediating
protein aggregation particularly in the crowding cellular environ-
ments [48]. Here we assessed the thermodynamic stability of T46I
by use of the urea-unfolding method previously for WT [32].
Markedly, unlike WT with a cooperative unfolding transition,
T46I shows a non-cooperative transition as well as reduced
stability (Figure 2a). T46I starts unfolding at a urea concentration
of ,1.6 M and shows no ending even at 8 M, while WT starts at
,3.5 M and ends at ,5.1 M. As a result of losing the cooperative
unfolding transition, the precise energy of thermodynamic stability
could not be fitted out from the T46I unfolding curve.
The loss of a cooperative unfolding transition of T46I implies
that its tight tertiary packing is disrupted to some degree [49,50]
and consequently the T46I molecule may be more accessible to
partially- or highly unfolded states prone to aggregation. Indeed,
we observed that aggregation occurred for T46I at high protein
concentrations and temperatures. For example, while at 45uC the
WT sample showed no precipitation and has almost no change of
the upfield peaks in the one-dimensional NMR proton spectra
(Figure 2b), a large portion of the T46I protein precipitated at
,42uC and the remaining protein has a dramatic structural
alteration as evidenced from the changes of the upfield peaks
(Figure 2c).
The high tendency of T46I to aggregate prevented from further
investigations on its dynamics on ps-ns and ms-ms time scales by
NMR relaxation measurements which require a sample with a
much higher concentration for collecting high-quality data.
Therefore, here we utilized NMR hydrogen/deuterium (H/D)
exchange and to assess the backbone dynamics for both WT and
T46I on minute-hour time scale. As well-established, in solution
labile hydrogens such as amide protons on proteins are continually
exchanging with the solvent at different rates, depending on a
variety of factors associated with their environment including their
exposure to the solvent or their involvement in H-bonds.
Consequence of the ALS-Causing T46I Mutation
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reflection of the exposure degree of amide protons to the solvent
[51]. Surprisingly, as seen in Figure 2d, even for WT in the buffer,
there are ,12% of 116 non-proline residues whose HSQC peaks
were not detectable. Upon subjecting to H/D exchange, ,66% of
the total residues have completely exchanged with deuterium
within the experimental dead time (15 min). These fast-exchange
rate residues cover not only most residues on the non-secondary
structure regions, but also on the b-strands and helical fragment
(Figure 2e). After 2.5 h, amide protons of more residues exchanged
and consequently only ,22% of the total residues have persisted
HSQC peaks, which were characterized as slow-exchange-rate
residues (Figures 2d and 2e). These results reveal that the hVAPB
MSP domain is very dynamic on the min-hr time scale, similar to
what we observed on the human ephrin-B2 [52]. Moreover, we
have also characterized the amide H/D exchanges for T46I and
no significant difference was found (data not shown), suggesting
that T46I has a largely unchanged dynamics on the min-hr time
scale.
Interactions of WT-/T46I-MSP domains to Nir2 peptide
The VAPB MSP domain was demonstrated to functionally
interact with the FFAT-motif containing Nir2 protein [11] and
previously we measured the dissociation constant (Kd) between the
WT-MSP domain and a Nir2 peptide to be 0.65 mM by ITC [32].
Here we assessed the binding of T46I to the same peptide under
the same conditions. The ITC result shows that T46I is still able to
bind the peptide but the affinity has a 3-fold reduction, with a Kd
of 2.2 mM (Figure 3a).
On the other hand, we also used HSQC titrations to visualize
the binding of the WT- and T46I-MSP domains to the Nir2
peptide. As shown in Figures 3b and 3c, in WT, for the residues
directly contacting the peptide [12,32], their HSQC peaks mostly
disappeared at a molar ratio of 1:2 (WT-MSP/Nir2), while for the
residues not directly contacting but close to the binding interface,
their HSQC peaks shifted (Figure 3c). Intriguingly, due to the
reduced affinity, the addition of the Nir2 peptide only induced the
shift, but not disappearance of the T46I HSQC peaks (Figure 3d).
Binding interactions of WT-/T46I-MSP domains to EphA4
Recently, the cleaved MSP domain was identified to serve as a
novel ligand for the EphA4 ligand binding domain [29] but the
underlying structural basis remains undefined. In the current
study, we attempted to gain thermodynamic parameters for the
EphA4-WT-MSP binding by ITC but unfortunately a complex
ITC profile was obtain (Figure 4a), which implies that the binding
may be involved in muti-sites or/and multi-steps. On the other
hand, this profile was no longer observed for the T46I-EphA4
interaction [data not shown], implying that the T46I mutation
significantly abolishes the binding.
Although previously we have successfully crystallized and
determined the crystal structures of the WT-MSP domain [32]
as well as EphA4 ligand binding domain in both free state [37] and
in complex with ephrin-B2 [40], we failed to crystallize the
Figure 1. Structural characterization of the T46I-MSP domain. (a). Far UV CD spectra of the WT- (blue), T46I- (red) and P56S- (black) MSP
domains at protein concentrations of 20 mM. (b). Superimposition of the two-dimensional
1H-
15N NMR HSQC spectra of the WT- (blue) and T46I- (red)
MSP domains at protein concentrations of 100 mM at pH 6.8. Ca (c) and Cb (d) chemical shifts of the WT- (blue) and T46I- (red) MSP domains. The
residues with the disappeared HSQC peaks are indicated by green arrows. (e). The crystal structure of the WT-MSP domain we previously determined
(32) to which the T46I residues with their HSQC peaks undetected were mapped. The two mutation residues causing ALS, P56S and T46I, were
displayed as spheres.
doi:10.1371/journal.pone.0027072.g001
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conditions. As such here we further gained the molecular details
for the binding interaction between EphA4 and MSP by NMR
HSQC titrations. First we monitored the change of the HSQC
spectra of the
15N-labeled WT- and T46-MSP domains upon
gradually adding the unlabeled EphA4 ligand binding domain. As
shown in Figure 4b, introduction of EphA4 induced shifts of few
peaks, but more dramatically disappearance of a set of peaks. If the
residues with shifted and disappeared HSQC peaks were mapped
back to the MSP structure, it appears that the significantly-
perturbed residues are located on E-F loop and several b-strands:
C-strand carrying Thr46, F- and G-strands (Figure 4c). By
contrast, addition of EphA4 to T46I resulted in almost no
disappearance the HSQC peaks, only caused slight peak shifts for
some residues (Figures 4d and 4e). These results indicate that the
T46I mutation dramatically disrupts the binding ability of the
MSP domain to EphA4, nicely in agreement with the above ITC
result.
We further addressed the binding by monitoring the HSQC
spectra of the EphA4 ligand-binding domain. As shown in
Figure 5a, addition of the WT-MSP protein even at a ratio of
1:2 (EphA4/WT-MSP) triggered extensive disappearance or
intensity-reduction of many EphA4 peaks, together with shifts of
few peaks. If the ratio was increased up to 1:8, most EphA4 peaks
disappeared. By mapping the residues with shifted or disappeared
peaks back to the EphA4 structure, it appears that the significantly
affected residues are located over D–E, G–H and J–K loops,
which have been previously established to directly contact it ligand
ephrins [40]. By a sharp contrast, addition of the T46I-MSP
domain caused almost no peak disappearance, but only shifts of
few peaks (Figures 5c and 5d), again indicating that the T46I
mutation dramatically eliminates the binding capability to EphA4.
To understand the underlying mechanism for the significant
disappearance of both MSP and EphA4 HSQC peaks, we
measured the radius of the EphA4 ligand binding domain by
dynamic light scattering (DLS) in the presence of both WT- and
T46I-MSP domains at different molar ratios but no significant
changes were observed (data not shown). This implies that the
binding triggers no formation of the tight EphA4-MSP complex
and no significant oligmerization. As such, the disappearance of
the MSP and EphA4 HSQC peaks is mostly resulting from the
increase of conformational exchanges on the ms-ms time scale
upon binding.
We also titrated the
15N-labeled EphA4 with the Nir2 peptide
but no change was detected for the EphA4 HSQC spectra even at
a ratio of 1:10 (EphA4/Nir2), thus clearly demonstrating that no
Figure 2. Stability of the T46I-MSP domain. (a). The urea-induced unfolding curves of the WT- (blue) and T46I- (red) MSP domains as reflected
by changes of the ellipticity at 222 nm with urea concentrations ranging from 0 to 8 M. One-dimensional NMR spectra of the WT- (b) and T46I- (c)
MSP domains at 15uC (green) 25uC (blue) and 45uC (red). (d). Hydrogen-deuterium (H/D) exchange results for the WT-MSP domain. Blue bars: residues
with HSQC peaks detectable in the 10 mM phosphate buffer at pH 6.8. Green bars: residues with HSQC peaks detectable 15 min after re-dissolving
the lyophilized protein powder in D2O. Red bars: residues with HSQC peaks detectable 2.5 hr after re-dissolving the lyophilized protein powder in
D2O. (e). The crystal structure of the MSP domain with the H/D exchange results mapped. The yellow is to indicate the residues undetectable even in
the 10 mM phosphate buffer at pH 6.8.
doi:10.1371/journal.pone.0027072.g002
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Strikingly, in the presence of the Nir2 peptide, addition of the
unlabeled WT-MSP domain was no longer able to induce shift/
disappearance of the EphA4 HSQC peaks even with the ratio
increased up to 1:10 (EphA4/MSP). This observation strongly
indicates that the binding of the Nir2 peptide to the MSP domain
would inhibit its further binding to EphA4, either by triggering the
structural change or occupying the EphA4 binding interface on
the MSP domain. If considering the fact that the MSP domain
show no significant change upon binding to ORP1, a FFAT-
containing peptide [12,32], the inhibition of the EphA4-MSP
binding by the Nir2 peptide might largely result from the
possibility that EphA4 and Nir2 peptide may have overlapped
binding interfaces on the MSP domain.
Based on the HSQC titration results, we also constructed the
model of the EphA4-MSP complex by HADDOCK and Figure 6a
presents the two lowest-energy models. Interestingly, although the
overall architecture of the EphA4-MSP complex bears some
similarity to the EphA4-ephrinB2 complex [40], some fundamen-
tal differences were observed. As previously uncovered, in all Eph-
ephrin complexes, the ephrin G-H loop inserts into the
hydrophobic ligand-binding channel of Eph receptor constituted
by the convex sheet of four b-strands together with the D-E, J-K,
and G-H loops (Figure 6b). Previously, by using NMR HSQC
titration, we showed that the EphA4 residues on the convex sheets
either disappeared or significantly shifted upon binding to
ephrinB2 [40]. However, in the EphA4-MSP complex there is
no MSP residues inserting into the EphA4 channel. Instead, the
MSP E–F loop is found to interact with EphA4 loops including G–
H and J–K loops (Figure 6a). This property is strongly supported
by our NMR results that no significant perturbation was observed
on the residues on the EphA4 convex sheets upon binding to the
MSP domain. From this model, binding residues on both MSP
and EphA4 are mostly located on loops which are thus highly
dynamic. As a consequence, the binding affinity between EphA4
and MSP is expected to be relatively-weak, which is consistent
with ITC and NMR results.
Also in the EphA4-MSP model, Thr46 sits in the central part of
the EphA4-MSP binding interface (Figure 6a), which rationalizes
the experimental observation that the mutation of Thr46 to Ile
dramatically abolishes its binding ability to EphA4. On the other
hand, in this model EphA4 and FFAT-containing peptide indeed
have overlapped binding interfaces on the MSP domain
(Figure 6c), thus nicely explaining another experimental observa-
tion that the binding of the Nir2 peptide to the MSP domain will
inhibit its further interaction with EphA4.
Molecular dynamics (MD) simulations of the WT-/T46I-
MSP domains
Our results reveal that the T46I mutation causes no significant
disruption of the native MSP structure, but it does lead to ALS.
This implies that the protein dynamics may play a key role beyond
the static structure, as we recently demonstrated on the SARS 3C-
like protease [36]. As such here we utilized the molecular
dynamics (MD) simulation to explore the dynamical behavior of
the MSP domain as well as the consequence of the T46I mutation.
Figures 7a and 7b present the root-mean-square deviations
(RMSD) of backbone atoms for two parallel simulations for both
WT- and T46I-MSP domains. It appears that for all simulations,
the RMS deviation values increased very rapidly during the first
0.1 ns. This is mostly due to the relaxations of the crystal structures
Figure 3. Interaction between the T46I-MSP domain and the Nir2 peptide. (a). The ITC titration profile of the binding reaction of the T46I-
MSP domain to the Nir2 peptide [upper panel]; and integrated values for reaction heats with subtraction of the corresponding blank results
normalized by the amount of ligand injected versus molar ratio of MSP/Nir2 (lower panel). Thermodynamic binding parameters obtained from fitting
the data are shown in the box. Superimposition of the two-dimensional
1H-
15N NMR HSQC spectra of the WT- (b) and T46I- (d) MSP domains in the
absence (black) and presence of the Nir2 peptide at molar ratios 1:0.5 (green), 1:1 (blue) and 1:2 (red). (c). Crystal structure of the VAPA MSP-ORP1
complex to illustrate the MSP-peptide binding interface [12].
doi:10.1371/journal.pone.0027072.g003
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MSP domains display no significant difference for overall
dynamical behaviors, as judged from their similar trajectories
and average RMSD values.
Snapshots of two independent simulations are presented in
Figures 8a and 8b respectively for the WT- and T46I-MSP
domains. As shown in Figures 7c and 7d which present the root-
mean-square fluctuation (RMSF) values versus the sequences,
although the global patterns of two independent simulations for
either WT or T46I are similar, there do exist some significant
differences over some local regions. This is due to the fact that the
systems behave non-ergodic in 15-ns simulations and as a
consequence the results would be influenced by the initial
conditions such as velocities. Interestingly, as seen in Figures 7e
and 7f, the WT-MSP residues with the RMSF value . the average
value include N-terminal Met1-Val7, Pro21 and Thr23 on A–B
loop, Arg50 on C–D loop, Phe76-Ly85 on E-F loop, Pro96-
Leu114 containing the unique helical fragment, and C-terminal
Phe123-Leu125 (Figure 8c). These residues were also found to be
highly dynamic on the min-hr time scale as captured by the H/D
exchange experiments.
Overall, the T46I-MSP domain has fluctuation patterns similar
to those of the WT-MSP domain (Figures 7c and 7d).
Nevertheless, increases of local fluctuations do occur for the
T46I-MSP domain. For example, in both simulations (Figures 7c
and 7d), several T46I regions show increased dynamics, which
include Gln13-Glu15 on the first proline-constrained S-shape loop
[32], Val44-Arg50 on C-strand and C-D loop covering the
mutation site Thr46; Pro80-Val90 on E-F loop and F-strand;
Glu103-Val105 on the helical fragment, and Met 115-Lys118 on
the G-strand (Figure 8d). On the other hand, we also calculated
the hydrogen bond occupancy for the WT and T46I simulations
and surprisingly only a small number of hydrogen bonds have the
occupancy difference larger than 10% between the WT- and
T46I-domains (Table 1). Nevertheless, residues with higher
fluctuations (Figure 8d) and significantly-reduced hydrogen bond
occupancy in T46I (Figure 8e) also overlap with those experi-
mentally mapped to be critical for binding to EphA4 and Nir2
peptide (Figures 4 and 5). As such, the simulation results suggest
that the dynamical changes triggered by the T46I mutation may at
least partly account for the loss of the binding affinity to EphA4
and Nir2 peptide.
Figure 4. Interaction between the WT-/T46I-MSP domains and EphA4. (a). The ITC titration profile of the binding reaction of the WT-MSP
domain to the ligand-binding domain of EphA4 (upper panel); and integrated values for reaction heats with subtraction of the corresponding blank
results normalized by the amount of ligand injected versus molar ratio of MSP/EphA4 (lower panel). Superimposition of the two dimensional
1H-
15N
NMR HSQC spectra of the WT- (b) and T46I- (d) MSP domains in the absence (blue) and presence of the EphA4 ligand binding domain at molar ratios
1:2 (green) and 1:8 (red) (MSP/EphA4). Red letters are used to label residues with disappeared HSQC peaks while blue for residues with shifted HSQC
peaks. The MSP structure with the perturbed residues mapped back for the interactions between the WT-MSP and EphA4 (c), and the T46I-MSP and
EphA4 (e). Blue is to indicate residues with unperturbed HSQC peaks, while green and red for residues with shifted and disappeared HSQC peaks
respectively.
doi:10.1371/journal.pone.0027072.g004
Consequence of the ALS-Causing T46I Mutation
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27072Figure 5. Interaction between EphA4 and WT-/T46I-MSP domain. Superimposition of the two-dimensional
1H-
15N NMR HSQC spectra of the
EphA4 ligand binding domain in the absence (blue) and presence of the WT- (a) and T46I- (c) MSP domains at molar ratios 1:2 (green) and 1:8 (red)
(EphA4/MSP). Red letters are used to label residues with disappeared HSQC peaks while blue for residues with shifted peaks. Crystal structure of the
EphA4 ligand-binding domain we previously determined (37) with the perturbed residues mapped back for the interaction between EphA4 and WT-
MSP (b), and T46I-MSP (d). Blue is to indicate residues with unperturbed HSQC peaks, while green and red for residues with shifted and disappeared
peaks respectively.
doi:10.1371/journal.pone.0027072.g005
Figure 6. Docking model for the EphA4-MSP complex. (a). Superimposition of two lowest energy docking model of the EphA4-MSP complex.
(b). The crystal structure we previously determined for the EphA4-ephrinB2 complex [40]. (c). The docking model of the EphA4-MSP complex with the
FFAT-containing ORP1 peptide displayed according to the VAPA MSP-ORP1 structure [12].
doi:10.1371/journal.pone.0027072.g006
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Last year, from non-Brazilian kindred the second mutation
T46I has been identified on the hVAPB MSP domain which also
causes a familial amyotrophic lateral sclerosis [6]. However, so far,
it remains completely unknown as how this mutation affects the
structure, stability, dynamics and binding function of the MSP
domain. In the present study, we aimed to address these issues by
utilizing both experimental and computational approaches. Unlike
the P56S-MSP domain with the entirely eliminated native
structure and binding capacity, the T46I-MSP domain still retains
the native secondary and tertiary structures, as evidently shown by
extensive CD and NMR characterization. Therefore, totally
different from P56S, T46I forms another class of the ALS-causing
MSP mutations which are analogous to some SOD1 mutants with
the native three-dimensional structure preserved [53,54].
Nevertheless, the T46I mutation does abolish the cooperative
urea-unfolding transition and reduce the thermodynamic stability
of the MSP domain. This allows the T46-MSP domain to more
easily access the partially- or/and highly-unfolded intermediates
which are prone to aggregation [32–35]. Indeed, if compared to
the WT-MSP domain, the T46I-MSP domain is much more
prone to aggregation at high protein concentration and temper-
ature. Moreover, as in cells macromolecular solutes are expected
to reach concentrations of .300 g/L and occupy .30% of the
volume [48,55–58], the tendency of the T46I mutant to aggregate
in cells should become more severe. It was once believed that in
macromolecular crowded cellular environments, the native state
should be stabilized by excluded-volume effects because it occupies
less space than the denatured state [48,55]. However, recent
studies of protein stability in cells uncover a surprising result;
proteins are either unaffected or destabilized in cells [56–58]. Now
it is proposed that the destabilization arises from a competition
between stabilizing excluded-volume effects and destabilizing
nonspecific interactions, in particular electrostatic interactions
which become predominant in the crowded cellular environment
[56–59]. As such, although the T46I-MSP domain still preserves
the native MSP structure in vitro, the T46I-triggered loss of the
cooperative unfolding and stability may be sufficient to cause
severe aggregation in macromolecular crowded cells, thus
rationalizing the previous in vivo observation [6].
Amyotrophic lateral sclerosis (ALS) was described more than
130 years ago, but it still remains a mystery whether any signaling
pathway is involved in ALS development. In this regard,
Figure 7. Trajectories of MD simulations. (a–b). Root-mean-square deviations (RMSD) of the backbone atoms for two independent MD
simulations of the WT- (blue) and T46I- (red) MSP domains. (c–d). Root-mean-square fluctuations (RMSF) of the Ca atoms computed for two
independent simulations (blue for simulation 1 and red for simulation 2) of the WT- (c) and T46I- (d) MSP domains. (e–f). Root-mean-square
fluctuations (RMSF) of the Ca atoms computed for two independent simulations for the WT- (blue) and T46I- (red) MSP domains. The average values
and standard deviations over 15 ns are computed and displayed. The green arrows are used to indicate the T46I-MSP residues with fluctuations larger
than those of the WT-MSP domain.
doi:10.1371/journal.pone.0027072.g007
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domain offers an unprecedented opportunity because two
signaling networks have been identified to be associated with the
VAPB MSP domain; one linked to lipid trafficking/metabolism
via binding to the FFAT-containing proteins; and another
connected to Eph-ephrin signaling, by acting as a novel ligand
Figure 8. Dynamical behaviors. (a–b). Structure snapshots (one structure for 1-ns interval) for two independent MD simulations for the WT- (blue)
and T46I- (red) MSP domains. (c). The MSP structure in which cyan is utilized to indicate the WT-MSP residues with RMSF values larger than the
average. (d). The MSP structure in which red is used to indicate T46I residues whose RMSF values are larger than those of the WT-MSP domain. The
two mutation residues causing ALS, P56S and T46I, were displayed as spheres. (e). The MSP structure in which green is used to indicate residues
whose hydrogen bonds occupancy difference is larger than 10% between WT and T46I while red is for residues whose hydrogen bonds occupancy
difference is larger than 10% between T46I and WT.
doi:10.1371/journal.pone.0027072.g008
Table 1. Hydrogen Bond Occupancy in MD simulations for the WT- and T46I-MSP Domains.
Residue Residue Type Atom Type Residue Residue Type Atom Type Average
a [WT] Average
a [T46I] Difference
b
19 ARG NE 124 GLU OE2 19.98 6.32 13.66
46 THR OG1 52 TYR O 27.84 0.00 27.84
46 THR OG1 87 LYS O 34.01 0.00 34.01
47 THR N 87 LYS O 86.24 64.35 21.89
51 ARG NH1 82 GLU OE1 14.91 3.26 11.65
51 ARG NH1 82 GLU OE2 17.28 1.76 15.52
51 ARG NH1 86 HIS NE2 55.69 13.35 42.34
76 PHE N 22 PHE O 29.82 49.10 219.27
84 SER OG 121 CYS O 3.90 24.24 220.34
a. The displayed values of the hydrogen bond occupancy are averaged over two independent simulations with 15 ns for WT- [wild-type] and T46I-MSP domains
respectively.
b. Only hydrogen bonds with the occupancy difference between WT and T46I .10% are displayed in this table.
doi:10.1371/journal.pone.0027072.t001
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only a 3-fold binding affinity reduction to the Nir2 peptide but
dramatically disruption of the binding capability to EphA4. In
particular, we reveal that the Nir2 peptide and EphA4 are most
likely to have overlapped binding interfaces on the MSP domain
and consequently the binding of the Nir2 peptide prevents the
MSP domain from further interacting with EphA4. This thus
raises an interesting possibility that the two signaling networks may
interplay in vivo. As a consequence, future studies on how they
interplay in vivo under physiological and ALS pathological
conditions may shed critical light on ALS pathogenesis.
With significant advances in experimental and computational
methodologies including NMR spectroscopy and MD simulations,
protein dynamics have been recently demonstrated to play a key
role in functions [36,60,61]. Here we also experimentally and
computationally explored the dynamical behaviors of both WT-
and T46I-MSP domains. Our H/D exchange results indicate that
even the WT-MSP domain is very dynamic on the min-hr time
scale, with fast-exchange rate residues located not only on most
loop regions, but also extensively over the helix and b-strands.
Furthermore, MD simulations unravel that although the T46I
mutation leads to no significant alteration of the overall dynamics,
it does trigger increases of fluctuations over several local regions.
Most amazingly, the residues with enhanced dynamics appear to
be involved in binding to both Nir2 peptide and EphA4. As such,
the T46I-triggered enhancement of local dynamics may also
contribute to the observed disruption of the binding capacity of the
MSP domain.
In conclusion, here we reveal that unlike the P56S mutation
which completely eliminates the native MSP structure, the T46I
mutation results in no dramatic structural disruption and
alteration of overall dynamics. Nevertheless, the T46I mutation
does leads to the loss of the cooperative unfolding transition and
reduction of thermodynamic stability, which consequently renders
the T46I-MSP domain to be prone to aggregation at high protein
concentrations and temperatures. Furthermore, the T46I muta-
tion leads to only a 3-fold affinity reduction to the Nir2 peptide but
remarkable loss in binding to EphA4. In particular, the overlapped
interfaces on the MSP domain for binding to EphA4 and Nir2
peptide strongly implies that two signaling networks may
functionally interplay in vivo. Future understanding how the
interplay alters under ALS pathological conditions may decipher
the mystery of ALS pathogenesis.
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